Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–32 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oakland, California
Conditions
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions
BYL719, AMG 479
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Terminated No phase listed Observational Accepts healthy volunteers

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

NCT04668521
Conditions
Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer
Interventions
OVA360
Other
Lead sponsor
Aspira Women's Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Conditions
Ovarian Neoplasms
Interventions
Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
Procedure
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Terminated No phase listed Observational

Natera Ovarian Cancer Detection Assay

NCT03485651
Conditions
Adnexal Mass
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Adnexal Mass, Ovarian Cancer
Interventions
Not listed
Lead sponsor
Fujirebio Diagnostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
San Diego, California • Fort Collins, Colorado • Jupiter, Florida + 10 more
Conditions
Ovarian Cancer, Adnexal Mass
Interventions
Method 1: Indocyanine green dye, Method 2: Indocyanine green dye, Method 3: Indocyanine green dye
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Neoplasm, Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Bay City, Michigan • Detroit, Michigan